Elevance Health stock faces a crucial Medicaid margin test

Elevance Health stock faces a renewed test of margin quality after the insurer raised its 2026 earnings outlook following third-quarter results that exceeded management's forecast. In an analysis published on November 5, Trefis said the central question for investors is whether Medicaid rates can catch up with medical costs while the company moves margins toward its longer-term targets.

Elevance Health stock traded at 383.90 euros on Lang & Schwarz at 13:20 CET on Monday, November 9, 2026.

Medical Costs Drive The Debate

Trefis reported that Elevance Health's net margin over the twelve months through September 30, 2026, was 2.5%, compared with 13.4% for the S&P 500. Management said the benefit expense ratio, which measures the share of premiums paid toward medical claims, stood at 90.6% in the third quarter, an improvement of 70 basis points.

That ratio remains a key operating gauge because small changes in medical costs can have a large effect on the portion of premium revenue left for administration and profit. The analysis therefore places the current investment case less on revenue scale alone and more on the durability of medical-cost control.

Medicaid Recovery Is Not Complete

Management expects full-year Medicare Advantage operating margin of at least 2%, below its long-term target range of 3% to 5%. It has described 2026 as the trough year for Medicaid margins and expects improvement in 2027, with a longer-term Medicaid margin target of 2% to 4%.

Trefis said management's October 21 comments indicated that Medicaid rates had not fully caught up with the underlying cost of care. The pace of recovery will therefore depend on future rate alignment and on actions to manage medical costs. The company has also said it is not relying on a single business to deliver its 2027 earnings growth.

Earnings Expectations Set The Next Hurdle

For 2026, management set adjusted earnings of at least 29 US dollars per share, alongside a baseline of at least 26.75 US dollars. The company expects adjusted diluted earnings per share to grow by at least 12% in 2027 from that baseline. Trefis noted that the third quarter included a net non-operating benefit of 1.85 US dollars per share, mainly from valuation adjustments in investment income, making the quality of future operating earnings especially relevant.

The next scheduled reporting point is expected in January 2027. Management is expected to provide more detail then on its 2027 assumptions, with investors likely to focus on the benefit expense ratio, Medicaid margin progress and the earnings outlook.

Investors can follow the real-time quote of Elevance Health stock for the latest trading indication.

For broader US equity-market context, see current S&P 500 market reports.

More news and analyses on Elevance Health stock cover the insurer's earnings, margins and outlook.

Source: Trefis analysis on Elevance Health, published November 5, 2026.